Lactovac Suspension for injection

Not authorised

- Bovine rotavirus A, strain 1005/78, Inactivated
- Bovine rotavirus A, strain Holland, Inactivated
- Bovine coronavirus, strain 800, Inactivated
- Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

Product identification

Medicine name:
Lactovac Suspension for injection

Active substance:
Bovine rotavirus A, strain 1005/78, Inactivated

Bovine rotavirus A, strain Holland, Inactivated

Bovine coronavirus, strain 800, Inactivated

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated

Target species:
Cattle

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Bovine rotavirus A, strain 1005/78, Inactivated
1.00 relative potency / 1.00 Dose

Bovine rotavirus A, strain Holland, Inactivated
1.00 relative potency / 1.00 Dose

Bovine coronavirus, strain 800, Inactivated
1.00 relative potency / 1.00 Dose

Escherichia coli, serotype O9:K35 (fimbrial adhesin F5 and F41), strain S1091/83, Inactivated
1.00 relative potency / 1.00 Dose

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Cattle**
  - Meat and offal. 0 day
  - Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Surrendered

Authorised in:

Netherlands

Package description:

Type I glass vial containing 5 ml. The glass vial is closed with a type I rubber stopper, sealed with an aluminium crimp cap. Cardboard box with 10 glass vials of 1 dose (5 ml).
Type I glass vial containing 25 ml. The glass vial is closed with a type I rubber stopper, sealed with an aluminium crimp cap. Cardboard box with 1 glass vial of 5 doses (25 ml).

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis B.V.

Marketing authorisation date:
1/07/2020

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 126398

Date of authorisation status change:
26/01/2022

Reference member state:
Ireland

Procedure number:
IE/V/0417/001/E/002

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.